PTO/SB/26 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and frademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PAGENTING

Under the Paperwork Reduction Act of 1995, no persons are required to re

Docket Number (Optional)

REJECTION OVER A "PRIOR" PATENT	PP001357.0124	
In re Application of: Robert Seid		
Application No.: 10/643,349		
Filed: August 19, 2003		
For: NEISSERIA MENINGITIDIS SEROGROUP B GLYCOCONJUGATES AND METHODS OF USING	THE SAME	
The owner*, Chiron Srl , of 100 percent interest in t except as provided below, the terminal part of the statutory term of any patent granted on the instant the expiration date of the full statutory term prior patent No. 6,638,513 as the term of said and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The granted on the instant application shall be enforceable only for and during such period that it and the pagreement runs with any patent granted on the instant application and is binding upon the grantee, its said the pagreement runs with any patent granted on the instant application and is binding upon the grantee, its said the pagreement runs with any patent granted on the instant application and is binding upon the grantee.	prior patent is defined in 35 U.S.C. 154 owner hereby agrees that any patent so prior patent are commonly owned. This	
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later:  expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a court of competent jurisdiction; is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reissued; or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.		
Check either box 1 or 2 below, if appropriate.  1. For submissions on behalf of a business/organization (e.g., corporation, partnership, university etc.), the undersigned is empowered to act on behalf of the business/organization.  I hereby declare that all statements made herein of my own knowledge are true and that all belief are believed to be true; and further that these statements were made with the knowledge that made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United	Il statements made on information and willful false statements and the like so	
statements may jeopardize the validity of the application or any patent issued thereon.  2.  The undersigned is an attorney or agent of record. Reg. No. 50,310		
Granture Signature	October 9 , 2006  Date	
Amy L. Hessler		
Typed or printed name		
	510-923-3833 Telephone Number	
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. PTO/SB/96 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OCT 1 1 2009 w

TO TRADENA

STATEMENT UNDER 37 CFR 3.73(b)		
Applicant/Patent Owner: <u>Chiron Srl</u>		
Application No./Patent No.: PP01357.0124	Filed/Issue Date: August 1	9, 2003
Entitled: NEISSERIA MENINGITIDIS SEROGROUP	B GLYCOCONJUGATES AND MET	HODS OF USING THE SAME
Chiron Srl (Name of Assignee)	, a <u>Corporation</u> (Type of Assignee, e.g., corpo	ration, partnership, university, government agency, etc.)
states that it is: 1.	terest; or	
<ol><li>an assignee of less than the entire right, titl (The extent (by percentage) of its ownership</li></ol>		
in the patent application/patent identified above b	y virtue of either:	
A An assignment from the inventor(s) of the p in the United States Patent and Trademark thereof is attached.	patent application/patent identifie Office at Reel, F	d above. The assignment was recorded rame, or for which a copy
OR  B. A chain of title from the inventor(s), of the p	patent application/patent identifie	d above, to the current assignee as follows:
1. From: Robert Seid  The document was recorded in the Reel 9016, Frame 0469	United States Patent and Trader	mark Office at
2. From: Chiron Corporation	To: Chiron Srl	
The document was recorded in the Reel 014377 , Frame 0	United States Patent and Trader	mark Office at copy thereof is attached.
From:  The document was recorded in the User Control of	To:	
The document was recorded in the Reel, Frame	United States Patent and Trader or for which a	mark Office at a copy thereof is attached.
Additional documents in the chain of title		
As required by 37 CFR 3.73(b)(1)(i), the docassignee was, or concurrently is being, submitted	cumentary evidence of the chain	of title from the original owner to the
[NOTE: A separate copy (i.e., a true copy of Division in accordance with 37 CFR Part 302.08]	the original assignment docume t 3, to record the assignment in t	nt(s)) must be submitted to Assignment the records of the USPTO. <u>See</u> MPEP
The undersigned (whose title is supplied below) is	s authorized to act on behalf of t	he assignee.
		October 9, 2006
Signature		Date
Amy L, Hessle	er	510-923-3833
Printed or Typed N	lame	Telephone Number
Patent Agent Title	· · · · · · · · · · · · · · · · · · ·	-

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.